edoxaban

Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].

D21-2393 subjects received a single-oral-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose.

Edoxaban Isomer is an impurity of Edoxaban, which is a novel inhibitor of factor Xa.

Edoxaban impurity 4, an impurity of Edoxaban (DU-176), is a selective, potent, and orally active inhibitor of factor Xa (FXa), exhibiting Kis of 0.561 nM for free FXa and 2.98 nM for prothrombinase. As an anticoagulant agent, Edoxaban is utilized for stroke prevention[1][2].

Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention[1][2]. [1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.[2]. Mendell J, Lee F, Chen S, The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovasc Pharmacol. 2013 Apr 23.

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Edoxaban-D6 (Standard) is a reference standard of Edoxaban-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Edoxaban-d6 is a deuterated compound of Edoxaban. Edoxaban has a CAS number of 480449-70-5. Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Edoxaban (DU-176b) hydrochloride is a potent, selective, orally active, direct inhibitor of Factor Xa (FXa), targeting human free FXa (Ki: 0.561 nM) and thrombinogenase (Ki: 2.98 nM). Over 10,000 times more selective than other thrombinases, it is suitable for studies to prevent thromboembolic disease.

Edoxaban Impurity 62 is a byproduct related to Edoxaban.

Edoxaban Impurity 57 is a byproduct associated with Edoxaban.

Edoxaban Impurity 63 is a byproduct associated with Edoxaban.

Edoxaban Impurity 49 is an impurity of Edoxaban.

Edoxaban Impurity 59 is a known impurity of Edoxaban.

Edoxaban Impurity 65 is an impurity of Edoxaban.

Edoxaban Impurity 8 is a byproduct associated with Edoxaban.

Edoxaban-D6 is a deuterated compound of Edoxaban. Edoxaban (T2368L) has a CAS number of 480449-70-5. Edoxaban (DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Edoxaban (Standard) is a reference standard for research and analysis in studies involving Edoxaban. Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].